DesignIn-vitro mechanistic study using excitatory cortical neurons differentiated from human induced pluripotent stem cells and exposed to cisplatin with or without NMN pretreatment.
PopulationHuman induced-pluripotent-stem-cell-derived excitatory cortical neurons; no enrolled human participants.
SampleMultiple independent cell experiments; mitochondrial ultrastructure analysis included 10–13 mitochondria per treatment from triplicate wells, with experiments repeated independently.
InterventionHuman cortical neurons were pretreated with NMN 500 μM for 30 minutes, then exposed to cisplatin 0.1 μM for 24 hours; the paper also references prior dose testing from 250–1,000 μM NMN.
EndpointsDNA damage (γ-H2AX); Mitochondrial reactive oxygen species; Mitochondrial membrane potential; ATP production; Mitochondrial ultrastructure, swelling, and cristae integrity
What the publication reported
This study used human iPSC-derived cortical neurons to model cisplatin-associated neurotoxicity in a controlled cell-culture system.
Cisplatin increased DNA damage and mitochondrial oxidative stress, lowered mitochondrial membrane potential and ATP production, and caused visible mitochondrial swelling and loss of cristae structure.
Pretreatment with NMN prevented or attenuated these mitochondrial defects in the cultured neurons. Because the study was entirely in vitro, it does not establish whether NMN prevents chemotherapy-related cognitive impairment in patients.
Key findings
Cisplatin increased DNA-damage signaling and mitochondrial reactive oxygen species in human iPSC-derived cortical neurons.
NMN pretreatment attenuated cisplatin-associated DNA-damage and oxidative-stress measures.
Cisplatin lowered mitochondrial membrane potential and ATP, while NMN pretreatment preserved both measures.
Transmission electron microscopy showed cisplatin-associated mitochondrial swelling and disrupted cristae, which were attenuated with NMN.
The findings support a mitochondrial mechanism in this cell model but do not measure cognition or clinical neurotoxicity.
What it cannot establish
The study used cultured neurons rather than patients receiving chemotherapy.
NMN was given as a short in-vitro pretreatment at micromolar concentrations, not as an oral clinical regimen.
The model isolates neuronal mitochondrial injury and cannot reproduce whole-brain, immune, vascular, pharmacokinetic, or behavioral effects.
The study did not evaluate cancer outcomes or whether NMN could interact with cisplatin's antitumor activity.
Clinical prevention of chemotherapy-induced cognitive impairment remains untested by this experiment.
HealthspanX claim boundary: This study does not establish that NMN prevents chemotherapy-induced cognitive impairment, is safe during cancer treatment, or should be combined with cisplatin in humans.
